offline
Healthcare | Biotechnology | USA -> http://www.pumabiotechnology.com/
Here's Why Puma Biotechnology Is Soaring Today
What happened
Shares of Puma Biotechnology (NASDAQ:PBYI) jumped over 43% today after the company announced fourth-quarter and full-year 2018 operating results. The business continues to reap the rewards of its successful and fast-growing cancer drug franchise, Nerlynx, which drove full-year revenue to $251 million. The company generated just $27.7 million in revenue in all of 2017.
More important for investors is the fact that Nerlynx sales have the business on the path to profitable operations. Puma Biotechnology reported a fourth-quarter 2018 operating loss of $18.6 million, compared to $63.6 million in the year-ago period. Full-year 2018 operating loss improved to $94.7 million, compared to $292.4 million in 2017.
...
So what
Nerlynx is approved as a stand-alone treatment for patients with HER2+ breast cancer after they've completed a regimen of Herceptin. Patients who take Nerlynx for one year are more likely to remain disease free five years later than those who don't. It's the only drug asset owned by Puma Biotechnology, but with analysts expecting peak annual sales of at least $1.2 billion, this one-trick pony might do just fine without a robust pipeline.
...
https://www.fool.com/investing/2019/03/0...today.aspx
![[Bild: PBYIc1dl1731.png]](https://finviz.com/publish/030119/PBYIc1dl1731.png)
Here's Why Puma Biotechnology Is Soaring Today
What happened
Shares of Puma Biotechnology (NASDAQ:PBYI) jumped over 43% today after the company announced fourth-quarter and full-year 2018 operating results. The business continues to reap the rewards of its successful and fast-growing cancer drug franchise, Nerlynx, which drove full-year revenue to $251 million. The company generated just $27.7 million in revenue in all of 2017.
More important for investors is the fact that Nerlynx sales have the business on the path to profitable operations. Puma Biotechnology reported a fourth-quarter 2018 operating loss of $18.6 million, compared to $63.6 million in the year-ago period. Full-year 2018 operating loss improved to $94.7 million, compared to $292.4 million in 2017.
...
So what
Nerlynx is approved as a stand-alone treatment for patients with HER2+ breast cancer after they've completed a regimen of Herceptin. Patients who take Nerlynx for one year are more likely to remain disease free five years later than those who don't. It's the only drug asset owned by Puma Biotechnology, but with analysts expecting peak annual sales of at least $1.2 billion, this one-trick pony might do just fine without a robust pipeline.
...
https://www.fool.com/investing/2019/03/0...today.aspx
